Q linea AB Cash Flow Conversion Efficiency
Q linea AB cash flow conversion efficiency. Based on the latest financial reports, Q linea AB (QLINEA) has a cash flow conversion efficiency ratio of -0.099x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-30.19 Million ≈ $-3.25 Million USD) by net assets (Skr304.55 Million ≈ $32.77 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Q linea AB (2016–2025)
Cash flow conversion efficiency of Q linea AB from 2016 to 2025. This chart illustrates how Q linea AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Q linea AB for real-time trading data and today's change.
Q linea AB Cash Flow Conversion Ratio Explained
Q linea AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Q linea AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Q linea AB ranked by their cash flow conversion efficiency. Also see market cap of Q linea AB for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
3D Energi Ltd
AU:TDO
|
-0.059x |
|
Adicet Bio Inc
NASDAQ:ACET
|
-0.165x |
|
Pharmx Technologies Ltd
AU:PHX
|
-0.559x |
|
Numulae Gestion de Servicios SOCIMI SA
MC:YNUM
|
-0.001x |
|
Mida Assets Public Company Limited
BK:MIDA
|
-0.061x |
|
KR1 PLC LS -0019
F:K4H
|
N/A |
|
Pasdec Holdings Bhd
KLSE:6912
|
-0.022x |
|
A-Tech Solution Co. Ltd
KQ:071670
|
-0.090x |
Annual Cash Flow Conversion Efficiency for Q linea AB (2016–2025)
The table below shows the annual cash flow conversion efficiency of Q linea AB from 2016 to 2025. Review Q linea AB free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr338.00 Million ≈ $36.37 Million |
Skr-162.12 Million ≈ $-17.45 Million |
-0.480x | -107.22% |
| 2024-12-31 | Skr-27.46 Million ≈ $-2.95 Million |
Skr-182.50 Million ≈ $-19.64 Million |
6.647x | +651.58% |
| 2023-12-31 | Skr189.64 Million ≈ $20.41 Million |
Skr-228.52 Million ≈ $-24.59 Million |
-1.205x | +22.36% |
| 2022-12-31 | Skr161.63 Million ≈ $17.39 Million |
Skr-250.86 Million ≈ $-27.00 Million |
-1.552x | -162.15% |
| 2021-12-31 | Skr430.79 Million ≈ $46.36 Million |
Skr-255.05 Million ≈ $-27.45 Million |
-0.592x | +5.14% |
| 2020-12-31 | Skr380.20 Million ≈ $40.92 Million |
Skr-237.31 Million ≈ $-25.54 Million |
-0.624x | -25.36% |
| 2019-12-31 | Skr340.94 Million ≈ $36.69 Million |
Skr-169.76 Million ≈ $-18.27 Million |
-0.498x | -108.34% |
| 2018-12-31 | Skr513.46 Million ≈ $55.26 Million |
Skr-122.71 Million ≈ $-13.21 Million |
-0.239x | +99.43% |
| 2017-12-31 | Skr1.51 Million ≈ $162.72K |
Skr-62.87 Million ≈ $-6.77 Million |
-41.577x | -565.28% |
| 2016-12-31 | Skr8.45 Million ≈ $909.79K |
Skr-52.83 Million ≈ $-5.69 Million |
-6.250x | -- |
About Q linea AB
Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, the United States, France, the Middle East, Belgium, Italy, and Finland. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disp… Read more